Oziva is a plant-based nutrition and wellness startup based in Mumbai, India, that sells supplements and nutrition products to consumers, and is majority-owned by Hindustan Unilever.

This Startup Deep Dive explains what Oziva does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Oziva in Brief

• What it is: Oziva is an Indian Plant-based nutrition D2C company based in Mumbai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• OZiva sells plant-based nutrition and wellness products to Indian consumers.
• Co-founder Aarti Gill has said most revenue came from its top 10 products.
• June 2020: reported $5 million Series A led by Matrix Partners India, with Titan Capital.
• Funding: About $17 million across 2 rounds (reported).

Oziva Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Oziva?

Oziva operates in the Plant-based nutrition D2C space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Oziva.

• OZiva sells plant-based nutrition and wellness products to Indian consumers.
• Co-founder Aarti Gill has said most revenue came from its top 10 products.

The Origin Story of Oziva

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Aarti Gill, Mihir Gadani.
• The company was founded in 2016 by Aarti Gill and Mihir Gadani.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Plant-based nutrition D2C sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• June 2020: reported $5 million Series A led by Matrix Partners India, with Titan Capital.
• March 2021: reported $12 million Series B led by Eight Roads Ventures.
• March 2021: company-stated that it crossed Rs 100 crore annualised recurring revenue and targeted Rs 500 crore ARR within three years.
• December 2022: Hindustan Unilever acquired a 51% stake, with the remaining 49% due after three years from completion of the first tranche (reported).

Oziva Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Series A, $5 million, June 2020, led by Matrix Partners India with Titan Capital (reported).
• Series B, $12 million, March 2021, led by Eight Roads Ventures with F-Prime Capital and Matrix Partners India (reported).
• HUL first tranche for 51%: cash consideration of Rs 264.28 crore (reported).

How Does Oziva Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Direct-to-consumer sale of plant-based nutrition products, with revenue concentrated in a limited set of top products (company-stated).

The Numbers: Oziva Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY23: revenue fell about 20%; net profit Rs 58.8 crore due to a one-time gain of Rs 95.5 crore, loss of Rs 45.8 crore excluding it.
• FY24: revenue about Rs 104 crore, up 4%; loss about Rs 43.5-44 crore (figures differ slightly by source).
• FY25: revenue Rs 258 crore, up 148%; loss narrowed about 90% to Rs 4.5 crore; advertising spend nearly doubled to Rs 120 crore.

Market Opportunity for Oziva

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Operates in India's health supplement and plant-based nutrition space.

Technology and Product at Oziva

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Core capability: Public detail on Oziva’s technology stack is limited beyond company-stated descriptions.
• Assessment lens: clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

Team and Culture at Oziva

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Aarti Gill and Mihir Gadani together own 36.22% (reported).

Oziva Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Oziva vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Oziva

• Revenue was flat in FY24 after a 20% fall in FY23, showing growth volatility.
• FY25 growth was accompanied by heavy advertising spend of Rs 120 crore, with total expenses of Rs 267 crore against revenue of Rs 258 crore.
• Founders' stake is now minority-held pending HUL's acquisition of the remaining 49%.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Oziva Growth Outlook: What to Watch

• HUL is due to acquire the remaining 49% roughly three years after completion of the first tranche.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Oziva can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Oziva Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Oziva

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Oziva.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Oziva

Studying a company in the Plant-based nutrition D2C space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Oziva.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Oziva as a Startup

• Customer clarity: Can Oziva name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Oziva is part of India’s growing Plant-based nutrition D2C ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Oziva FAQs: Frequently Asked Questions

What is Oziva?

OZiva is a plant-based nutrition and wellness startup based in Mumbai, India, that sells supplements and nutrition products to consumers, and is majority-owned by Hindustan Unilever. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Oziva?

Oziva was founded by Aarti Gill, Mihir Gadani, and the company reports a founding year of 2016.

How much funding has Oziva raised?

About $17 million across 2 rounds (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Oziva make money?

Oziva earns revenue from its Plant-based nutrition D2C products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Oziva?

Competitors of Oziva depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Oziva?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Vasundharaa Geo Technologies — short profile of what is publicly known | Cosmoserve Space — Hyderabad startup with a Venus flytrap-style debris catcher. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.